Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company’s lead molecule, FXR314, the non-steroidal, non-bile acid FXR agonist, is being developed for the treatment of metabolic function-associated steatohepatitis (MASH).
Lead Product(s): FXR314
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FXR314
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
FXR314, an FXR agonist, has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis.
Lead Product(s): FXR314
Therapeutic Area: Gastroenterology Product Name: FXR314
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
Unanticipated late opposition by major Organovo stockholder results in termination of proposed merger agreement.
Lead Product(s): Locnartecan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Tarveda Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 07, 2020
Details:
This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.
Lead Product(s): 2G-Dabocins
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Mutabilis
Deal Size: $11.9 million Upfront Cash: Undisclosed
Deal Type: Investment January 06, 2020